A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Latest Information Update: 25 Mar 2022
At a glance
- Drugs SIR1 365 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 23 Mar 2022 Status changed from active, no longer recruiting to completed.
- 23 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2021 New trial record